AML Therapy With Irradiated Allogeneic Cells

Related Clinical Trial
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia AML Therapy With Irradiated Allogeneic Cells Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)

Brief Title

AML Therapy With Irradiated Allogeneic Cells

Official Title

AML Therapy With Irradiated Allogeneic Cells

Brief Summary

      This pilot clinical trial studies if cells donated by a close genetic relative can help
      maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive
      a standard induction chemotherapy. If a complete remission results they will receive
      irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR
      after the standard induction chemotherapy are eligible for the experimental therapy
      (irradiated haploidentical cells).
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. Toxicity of haploidentical allogeneic cellular therapy in patients in complete remission
      (CR) (or CR with incomplete platelet recovery [CRp]) after induction chemotherapy with
      fludarabine (fludarabine phosphate)-cytarabine.

      II. Efficacy of haploidentical allogeneic cellular therapy in patients in CR (or CRp) after
      induction chemotherapy with fludarabine-cytarabine (remission rates at 6, 12, 18, 24 months).

      SECONDARY OBJECTIVES:

      I. Immunologic parameters before and after haploidentical therapy: host anti-leukemia T
      cells; host regulatory T cells.

      OUTLINE:

      INDUCTION CHEMOTHERAPY: Patients receive fludarabine phosphate intravenously (IV) over 1 hour
      once daily (QD) for 5 days and cytarabine IV over 4 hours for 5 days. Treatment may continue
      for 1 or 2 courses at the discretion of the treating physician.

      ALLOGENEIC CELLULAR THERAPY: Patients undergo irradiated donor lymphocyte infusion (DLI) of 3
      x 10^8 cluster of differentiation (CD)3+ cells/kg at 8 weeks. Patients with stable disease
      may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically for up to 2 years.
    


Study Type

Interventional


Primary Outcome

Adverse Events Related to Experimental Therapy

Secondary Outcome

 Progression Free Survival Probability for CR

Condition

Adult Acute Megakaryoblastic Leukemia (M7)

Intervention

fludarabine phosphate

Study Arms / Comparison Groups

 Standard chemotherapy followed by allogenic therapy
Description:  INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

6

Start Date

February 2014

Completion Date

December 16, 2015

Primary Completion Date

December 16, 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically proven non-M3 AML:

               -  Refractory/relapsed AML OR

               -  Initial diagnosis of AML in patient >= 60 years old

          -  Total bilirubin =< 1.5 times upper limit of normal (ULN) institutional limits (unless
             Gilbert's disease)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 X institutional ULN

          -  Cardiac left ventricular ejection fraction (LVEF) >= 35%

          -  Serum creatinine =< 1.5 mg/dl

          -  Any organ dysfunction thought to be secondary to disease will be considered separately
             and the patient will be included at the investigators discretion

          -  Patients must give informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3

          -  Must have a potential haploidentical donor (parent, sibling, child)

          -  A patient is eligible for second enrollment (allo-cellular therapy) if all of the
             following inclusion criteria are met:

          -  Patient must have documented CR or CRp after 1 or 2 cycles of fludarabine + cytarabine

          -  Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)

          -  Patient must have a partially (>= 3/6 class I antigen) human leukocyte antigen
             (HLA)-matched (by serology or low resolution deoxyribonucleic acid [DNA] testing)
             relative able to serve as a donor

          -  Patients must not have active uncontrolled infections, other medical or
             psychological/social conditions that might increase the likelihood of patient adverse
             effects or poor outcomes

          -  Total bilirubin < 1.5 times upper limit of normal (ULN) institutional limits (unless
             Gilbert's disease)

          -  AST(SGOT)/ALT(SGPT) =< 2.5 X institutional ULN

          -  Serum creatinine < 2.0 mg/dl

          -  ECOG performance status =< 2

          -  DONOR: donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched

          -  DONOR: donor must meet all New Brunswick Affiliated Hospitals (NBAH) requirements for
             hematopoietic stem cell donation, including:

          -  DONOR: age >= 18 years old

          -  DONOR: white blood cells (WBC) 4.0-10.0 x 10^3/mm^3

          -  DONOR: platelet count 150,000 to 440,000/mm^3

          -  DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%

          -  DONOR: not pregnant or lactating

          -  DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV),
             hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B
             surface antigen (HB S ag) (-); meet other infectious disease screening criteria
             utilized by NBAH Blood Center

          -  DONOR: no uncontrolled infections, other medical or psychological/social conditions,
             or medications that might increase the likelihood of patient or donor adverse effects
             or poor outcomes

          -  DONOR: meet other blood bank criteria for blood product donation (as determined by
             NBAH Blood Center screening history and laboratory studies)

        Exclusion Criteria:

          -  History of current or prior medical problems that the investigator feels will prevent
             administration of therapy or assessment of response due to excess toxicity

          -  Patients with known active central nervous system (CNS) leukemia will be excluded from
             this clinical study

          -  Known HIV-positive patients are excluded from the study

          -  Patients may not be pregnant or breast feeding
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Roger Strair, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02105116

Organization ID

021208

Secondary IDs

NCI-2013-02408

Responsible Party

Principal Investigator

Study Sponsor

Rutgers, The State University of New Jersey

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Roger Strair, MD, PhD, Principal Investigator, Rutgers Cancer Institute of New Jersey


Verification Date

June 2018